TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03575598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Sitravatinib (MGCD516) is an orally-available, potent small molecule inhibitor of a closely related spectrum of tyrosine kinases, which has shown antitumor activity in a variety of in vitro and in vivo model systems.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (OPDIVO®) is a human IgG4 kappa immunoglobulin that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.
Study: NCT03484897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P927 - LICHTENA DermAD CREMA CORPO
Description: The study cream was applied once a day (at the morning or at the evening), preferentially always at the same hour, with a mild massage, for an uninterrupted period of 1 month
Study: NCT02116023

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Orange flavored beverage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange flavored beverage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange flavored beverage
Study: NCT05975424

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: Observational study; annual MRI for first 5 years only to monitor changes in the injection site
Study: NCT01055340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxyntomodulin (OXM)
Description: Single infusion of OXM 3.0 pmol/kg/min by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxyntomodulin (OXM)
Description: Single infusion of OXM 3.0 pmol/kg/min by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxyntomodulin (OXM)
Description: Single infusion of OXM 3.0 pmol/kg/min by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxyntomodulin (OXM)
Description: Single infusion of OXM 3.0 pmol/kg/min by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxyntomodulin (OXM)
Description: Single infusion of OXM 3.0 pmol/kg/min by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxyntomodulin (OXM)
Description: Single infusion of OXM 3.0 pmol/kg/min by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Oxyntomodulin (OXM)
Description: Single infusion of OXM 0.6 pmol/kg/min by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Oxyntomodulin (OXM)
Description: Single infusion of OXM 0.6 pmol/kg/min by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Oxyntomodulin (OXM)
Description: Single infusion of OXM 0.6 pmol/kg/min by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Oxyntomodulin (OXM)
Description: Single infusion of OXM 0.6 pmol/kg/min by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Oxyntomodulin (OXM)
Description: Single infusion of OXM 0.6 pmol/kg/min by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Oxyntomodulin (OXM)
Description: Single infusion of OXM 0.6 pmol/kg/min by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo [ hemaccel-containing saline]
Description: Single Placebo infusion of hemaccel-containing saline by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo [ hemaccel-containing saline]
Description: Single Placebo infusion of hemaccel-containing saline by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo [ hemaccel-containing saline]
Description: Single Placebo infusion of hemaccel-containing saline by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo [ hemaccel-containing saline]
Description: Single Placebo infusion of hemaccel-containing saline by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo [ hemaccel-containing saline]
Description: Single Placebo infusion of hemaccel-containing saline by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo [ hemaccel-containing saline]
Description: Single Placebo infusion of hemaccel-containing saline by IV
Study: NCT03247101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miyarisan-BM (Clostridium Butyricum Miyairi)
Description: 40mg po tid x 6months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urso group
Description: ursodoxycholic acid, 200mg po tid x 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biotase group
Description: Biotase 1# \[Biodiastase 30mg + lipase 65mg + newlase 10mg\]/tab po tid x 6 months
Study: NCT01930500

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual neuropsychological rehabilitation
Description: Psychoeducation, teaching compensatory strategies and offering psychological support to better cope with dyslexia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group based neuropsychological rehabilitation
Description: Psychoeducation, teaching compensatory strategies and offering psychological support and peer support to better cope with dyslexia
Study: NCT04876287

Intervention type: DRUG
Intervention: Radioiodine
Description: cancer therapy

Intervention type: DRUG
Intervention: Radioiodine
Description: cancer therapy
Study: NCT02489279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sustained Attention Control (SAC) Method
Description: Participants use the software for 5 minutes, 3 times per day, 5 days per week, for 10 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Scrabble
Description: Participants use the software for 5 minutes, 3 times per day, 5 days per week, for 10 weeks.
Study: NCT03446690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MI Varnish
Description: MI Varnish with RECALDENT™ (CPP-ACP) enhances enamel acid resistance and boosts salivary fluoride levels. This product remains on the teeth longer than other fluoride varnishes and contains high levels of fluoride and calcium released in the oral cavity. The difference is in the RECALDENT™ (CPP-ACP), which makes MI Varnish a natural and unique choice for your patients. Casein phosphopeptides (CPP) naturally occurs in milk casein; Amorphous Calcium Phosphate (ACP), which is found in the RECALDENT™, is also the source of calcium and phosphate. In the oral cavity, CPP binds to oral surfaces such as teeth, dentin, oral mucosa and biofilm. Calcium and phosphate ions are the building blocks for healthy teeth and MI Varnish delivers bioavailable calcium and phosphate ions into the saliva.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Participants received routine treatment and oral hygiene regimes. No intervention for this group.
Study: NCT02101255

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Curodont Repair
Description: Self-assembling peptide, biomimetic re-mineralisation~Application on Day 0 and Day 360

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride
Description: Application on Day 0, Day 180, Day 360, Day 540
Study: NCT00973128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMCSF plus Antimony reduced dose
Description: 400 µg, divided in two doses a week apart, antimony (20mg/daily for 10 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meglumine antimoniate
Description: 20mg/daily for 20 days
Study: NCT00497497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: (Only for patients not previously treated with bevacizumab) Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI regimen
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO95780
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO95780
Description: Intravenous repeating dose
Study: NCT01344356

Intervention type: RADIATION
Group type: OTHER
Intervention: stereotactic body radiotherapy
Description: 14-16 Gy / 1 fraction OR 18-21 Gy / 3 fractions (6-7 Gy per fraction)OR 25-45 Gy / 5 fractions (5-9 Gy per fraction)

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic body radiotherapy
Description: 8-12 Gy / 1 fraction OR 12-18 Gy / 3 fractions (4-6 Gy per fraction) OR 35-45 Gy / 5 fractions (7-9 Gy per fraction)
Study: NCT01943227

Intervention type: OTHER
Intervention: controlled positive pressure ventilation 9ml/kg tidal volume
Description: controlled positive pressure ventilation 9ml/kg tidal volume

Intervention type: OTHER
Intervention: controlled positive pressure ventilation 6ml/kg tidal volume
Description: controlled positive pressure ventilation 6ml/kg tidal volume
Study: NCT04120467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance
Description: One group will receive a 60-minute dance class weekly over a 6 weeks period. A physiotherapist - dance teacher will lead the classes, supported by at least one volunteer.~The class structure will consist of five components: warm up (10 minutes), technical exercises (10 minutes), improvisation (15 minutes), a short routine (15 minutes) and a cool down/feedback time (10 minutes). Dance exercises will be targeting flexibility, balance, endurance, upper and lower limbs functions, interaction between dancers, perception and memory. Using choreography or short routine, the class will include repeating the dance moves - which fosters memorization - and also the additional challenge of remembering a sequence of moves.~Given the great variability of each participant's functional ability, the complexity and the intensity of the dance exercises will progress according to each participant's capacity, in order to fulfill an appropriate challenge at moderate treatment intensity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitation
Description: The control group will have conventional rehabilitation as usually planned in the rehabilitation center: 45 to 60 minutes of physiotherapy per day integrating sensory stimulation, motor activation, strengthening, coordination, balance and exercise training. Patients also receive 45 to 60 minutes of occupational therapy per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard rehabilitation
Description: The control group will have conventional rehabilitation as usually planned in the rehabilitation center: 45 to 60 minutes of physiotherapy per day integrating sensory stimulation, motor activation, strengthening, coordination, balance and exercise training. Patients also receive 45 to 60 minutes of occupational therapy per day.
Study: NCT01096004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4017
Description: oral suspension, 1200mg, once daily, for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02834364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: 450 mg p.o. once daily. One cycle is defined as 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: 45 mg p.o. twice daily. One cycle is defined as 28 days
Study: NCT03859219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Description: * Pharmaceutical form: solution for injection~* Route of administration: subcutaneous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Description: * Pharmaceutical form: solution for injection~* Route of administration: subcutaneous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Description: * Pharmaceutical form: solution for injection~* Route of administration: subcutaneous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Description: * Pharmaceutical form: solution for injection~* Route of administration: subcutaneous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Description: * Pharmaceutical form: solution for injection~* Route of administration: subcutaneous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Description: * Pharmaceutical form: solution for injection~* Route of administration: subcutaneous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Description: * Pharmaceutical form: solution for injection~* Route of administration: subcutaneous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Description: * Pharmaceutical form: solution for injection~* Route of administration: subcutaneous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Pharmaceutical form: solution for injection~* Route of administration: subcutaneous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Pharmaceutical form: solution for injection~* Route of administration: subcutaneous infusion
Study: NCT01750554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intermediate-acting digital nerve block
Description: non-therapeutic Bupivacaine digital nerve block to assess effect on accuracy of diagnostic readings
Study: NCT04394975

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sunitinib
Description: Drug: Sunitinib, oral capsule
Study: NCT03859219

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Pharmaceutical form: solution for injection~* Route of administration: subcutaneous infusion
Study: NCT01729819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine tartrate extended release capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine tartrate extended release capsules
Study: NCT03463655

Intervention type: DIAGNOSTIC_TEST
Intervention: cirrhotic albumin
Description: Ascites puncture

Intervention type: DIAGNOSTIC_TEST
Intervention: serum albumin
Description: blood punctures
Study: NCT03682367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Use of Gabapentin peri- and post-operatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Concentrate
Description: Use of sugar-free Placebo peri- and post-operatively.
Study: NCT00123630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: omalizumab dosed IV based on IgE level and weight every 2 - 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given IV once every 2-4 weeks based on weight
Study: NCT00760760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reesterified long-chain n-3 polyunsaturated fatty acids (EPA, DHA)
Description: 4g daily, 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: equivalent amount of fat as butter
Study: NCT00916123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-J591
Description: Two infusions of 177Lu-DOTA-J591 at 30 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-J591
Description: Two infusions of 177Lu-DOTA-J591 at 35 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
Study: NCT03091855

Intervention type: OTHER
Intervention: Questionnaire
Description: Alzheimer's Disease Assessment Scale (ADAS-cog11) and Disability Assessment for Dementia (DAD) Questionnaires

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: MRI at baseline and at 24 months post-enrollment for 20 sub-study participants
Study: NCT02998307

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPR Training
Description: Brief CPR assessment and training done during working hours with real-time performance feedback
Study: NCT04111575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Music Therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Music Therapy
Study: NCT01227317

Intervention type: OTHER
Intervention: Prognostic value of Biomarkers
Description: Mr pro ADM, Mr pro ANP, PCT, Copeptin and pro endothelin value to stratify the risk in SOB patients
Study: NCT04627246

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Dendritic Cell Vaccine Loaded with Personalized Peptides (PEP-DC vaccine)
Description: SOC: Subgroup1: intravenous mFOLFIRINOX for twelve 14-day cycles. Subgroup2: intravenous gemcitabine twice, on days 1 and 8, and oral capecitabine for 14 days of 21-day cycles, for eight cycles.~PEP-DC vaccine: At least 5 subcutaneous vaccinations starting on cycle 8 (subgroup1) or cycle 5 (subgroup2) of chemotherapy: Subgroup1: every 4 weeks, on day 3 of every second 14-day cycle, and then every 4 weeks starting from the first nivolumab administration. Subgroup2: Every 3 weeks, on day 9 of each 21-day cycle, and then every 4 weeks starting from the second nivolumab administration.~Nivolumab: intravenous, starting after the last chemotherapy cycle. Administered as a flat dose of 240mg every 2 weeks during the vaccination period until the last vaccine dose or at least for 8 weeks after the end of last chemotherapy cycle if vaccination stops earlier. Then, as a maintenance therapy at 480 mg every 4 weeks until appearance of new lesions or unacceptable toxicity for a maximum of 2 years.
Study: NCT03519178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06873600
Description: PF-06873600 tablet for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06873600
Description: PF-06873600 tablet for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06873600
Description: PF-06873600 tablet for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06873600
Description: PF-06873600 tablet for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06873600
Description: PF-06873600 tablet for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06873600
Description: PF-06873600 tablet for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06873600
Description: PF-06873600 tablet for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06873600
Description: PF-06873600 tablet for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy 1
Description: Endocrine Therapy 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy 1
Description: Endocrine Therapy 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy 1
Description: Endocrine Therapy 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy 2
Description: Endocrine Therapy 2
Study: NCT02998307

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPR Training
Description: Brief CPR assessment and training done during working hours with real-time performance feedback

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPR Training
Description: Brief CPR assessment and training done during working hours with real-time performance feedback
Study: NCT03519178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy 2
Description: Endocrine Therapy 2
Study: NCT01599195

Intervention type: DEVICE
Intervention: AudioDoc
Description: AudioDoc will be used to identify the carotid and femoral bruit
Study: NCT04118504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: Lifestyle intervention on through mobile application
Study: NCT03412760

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Exome sequencing
Description: Expansive genetic test performed for affected fetus or neonate.
Study: NCT00586625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepreve
Description: One drop, both eyes, twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One drop, both eyes, twice a day
Study: NCT02831140

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early exercises
Description: In postoperative phase:~Early exercises: within the first hour ;setting a half bed position, deep breathing and coughing . In the second hour, curbing vagal malaise and performing relaxation movements. In the third hour, walking about 20 to 30 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Removing urinary probe and all catheters.
Description: In postoperative phase : Removing urinary probe and all catheters.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early alimentation
Description: In postoperative phase :Early alimentation: in the first hour to the second hour .

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: commun interventions
Description: * In preoperative phase: stopping smoking at least 2 weeks, hospitalization and balanced alimentation one day before the surgery.~* In peroperative phase : no use of benzodiazepines in the anesthesia , selective intubation , maintaining vital parameters as normal and using a mini invasive surgical approach ( video thoracoscopy , video assisted thoracoscopy , thoracotomy with preservation of the posterior muscles of the chest wall~  , preservation of Serratus anterior and the front part of Latissimus Dorsi ).~* In postoperative phase : Immediate extubation ( less than 30 minutes from the surgery end) , peridural or paravertebral or intercostal block analgesia , no use of abusive antibiotic , all analgesic drugs are permitted if there are no contraindications and physiotherapy from the 6th hour.
Study: NCT01052571

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lumbar transforaminal epidural injections
Description: with an injection of local anesthetic or with 1% lidocaine or 0.25% bupivacaine with 3 mg of steroid per level

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lumbar transforaminal epidural injections
Description: with an injection of local anesthetic or with 1% lidocaine or 0.25% bupivacaine with 3 mg of steroid per level
Study: NCT01752985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-813160
Study: NCT00916123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-J591
Description: Two infusions of 177Lu-DOTA-J591 at 40 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
Study: NCT01752985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-813160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-813160

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching with BMS-813160